We heard great presentations this week from Dr. Moore, who works with the Institutional Review Board at Virginia Tech, and from Dr. Van Dyke, who works between science and entrepreneurship. They both talked about different legs of moving your research from “bench to bedside” or from the lab into animal and human subjects and to market.
Was there anything that you found surprising about the IRB process from Dr. Moore’s presentation?
Did you find anything curious or unusual in thinking through the larger picture – funding, production, patenting, and research – that Dr. Van Dyke described?
What things hadn’t you considered before?